Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Check-Cap Ltd. stock logo
CHEK
Check-Cap
$2.29
+3.2%
$2.25
$1.27
$4.63
$13.40M0.28208,382 shs5,478 shs
COT
Cotinga Pharmaceuticals Inc. (COT.V)
C$0.04
-41.7%
C$0.03
C$0.02
C$0.12
C$770KN/A20,281 shs1,000 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.23
-2.3%
$3.85
$2.70
$11.55
$8.42M2.2642,970 shs2,768 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Check-Cap Ltd. stock logo
CHEK
Check-Cap
-3.06%+1.83%+15.03%+3.73%+65.67%
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.00%0.00%0.00%0.00%0.00%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-5.04%+21.29%+6.13%+41.97%-61.88%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Check-Cap Ltd. stock logo
CHEK
Check-Cap
0.3011 of 5 stars
0.02.00.00.03.20.01.3
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Check-Cap Ltd. stock logo
CHEK
Check-Cap
2.00
HoldN/AN/A
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Check-Cap Ltd. stock logo
CHEK
Check-Cap
N/AN/AN/AN/A$8.57 per shareN/A
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/AN/AC$0.00 per share17.50C($0.18) per shareN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.43N/AN/A$13.18 per share0.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Check-Cap Ltd. stock logo
CHEK
Check-Cap
-$19.11M-$3.02N/AN/AN/AN/A-47.85%-43.50%5/9/2024 (Estimated)
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/A-C$0.12N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)

Latest CHEK, NURO, ADR, and COT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Check-Cap Ltd. stock logo
CHEK
Check-Cap
N/AN/AN/AN/AN/A
COT
Cotinga Pharmaceuticals Inc. (COT.V)
C$0.24685.71%N/AN/A N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Check-Cap Ltd. stock logo
CHEK
Check-Cap
N/A
17.60
17.60
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/A
0.05
0.01
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Check-Cap Ltd. stock logo
CHEK
Check-Cap
1.07%
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%

Insider Ownership

CompanyInsider Ownership
Check-Cap Ltd. stock logo
CHEK
Check-Cap
0.48%
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Check-Cap Ltd. stock logo
CHEK
Check-Cap
855.85 million5.82 millionNot Optionable
COT
Cotinga Pharmaceuticals Inc. (COT.V)
N/A21.99 millionN/ANot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable

CHEK, NURO, ADR, and COT Headlines

SourceHeadline
NeuroMetrix, Inc.s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year
finance.yahoo.com - April 24 at 9:11 AM
NeuroMetrix appoints new board director, ends ATM facilityNeuroMetrix appoints new board director, ends ATM facility
investing.com - April 20 at 6:57 PM
NeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement Steps
markets.businessinsider.com - April 19 at 2:51 PM
NeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
finanznachrichten.de - April 19 at 9:50 AM
NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNeuroMetrix Announces Steps Taken to Enhance Shareholder Value
globenewswire.com - April 19 at 8:00 AM
NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
globenewswire.com - March 14 at 9:00 AM
NeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell Fibromyalgia
finanznachrichten.de - March 13 at 10:19 PM
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
globenewswire.com - March 13 at 9:00 AM
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be FiredEcho Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
accesswire.com - March 12 at 8:00 AM
RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
finanznachrichten.de - March 8 at 2:12 PM
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
finance.yahoo.com - March 8 at 2:12 PM
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
accesswire.com - March 4 at 8:00 AM
Google releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernames
au.lifestyle.yahoo.com - February 25 at 9:19 AM
NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)
finance.yahoo.com - February 24 at 12:41 PM
NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 23 at 4:00 PM
NeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
finanznachrichten.de - February 22 at 8:37 AM
NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
finance.yahoo.com - February 22 at 8:37 AM
NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
globenewswire.com - February 22 at 7:00 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
finance.yahoo.com - February 15 at 11:31 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
globenewswire.com - February 15 at 9:00 AM
NeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
finanznachrichten.de - February 13 at 4:30 PM
NeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock Drops
markets.businessinsider.com - February 13 at 4:30 PM
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
finance.yahoo.com - February 13 at 10:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Check-Cap logo

Check-Cap

NASDAQ:CHEK
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Cotinga Pharmaceuticals Inc. (COT.V)

CVE:COT
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.